The implications of myasthenia gravis for the anaesthesiologist

被引:0
作者
Mamoojee, A. I. [1 ]
机构
[1] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Dept Anaesthesia, Johannesburg, South Africa
关键词
myasthenia gravis; anaesthesia;
D O I
10.36303/SAJAA.2021.27.6.S1.2695
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Myasthenia gravis is an autoimmune disease in which antibodies which are generated to the acetylcholine nicotinic receptors at the motor end plate cause skeletal muscle weakness.(1) There appears to be an association with the thymus gland, where T cells generate antibodies after being sensitised to a protein similar to the acetylcholine receptor.(1) Historically, myasthenia gravis was classified into five classes by Osserman, ranging from eye involvement alone, to mild, moderate or severe weakness, and the need for intubation and ventilation.(1) Patients with myasthenia gravis are commonly treated with the acetylcholinesterase inhibitor, pyrodistigmine, glucocorticosteroids, other immune suppressants, as well as plasma exchange and intravenous immunoglobulins. Patients with generalised disease may present for surgery to remove the thymus gland, after which approximately 75% of patients enter remission.(1) In the perioperative period, the nuances of the disease process must be appreciated in order to provide the most beneficent care. Neuromuscular blockade should be avoided unless absolutely necessary, and when non-depolarising agents are used, they must always be accompanied by monitoring of the neuromuscular junction and appropriately reduced doses, due to the increased sensitivity to these agents. Sugammadex should also be available. These patients are relatively resistant to succinylcholine, and an increased dose should be used with the knowledge that prolonged blockade may ensue.(1)
引用
收藏
页码:S167 / S169
页数:3
相关论文
共 50 条
  • [11] Myasthenia gravisMyasthenia gravis
    W. A. Nix
    P. P. Urban
    Notfall & Rettungsmedizin, 2005, 8 (4): : 275 - 280
  • [12] Myasthenia gravis and sleep
    Stepansky, R
    Zeitlhofer, J
    WIENER KLINISCHE WOCHENSCHRIFT, 2001, 113 (7-8) : 285 - 287
  • [13] Thymectomy for myasthenia gravis
    Urschel, JD
    Grewal, RP
    POSTGRADUATE MEDICAL JOURNAL, 1998, 74 (869) : 139 - 144
  • [14] Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity
    Huijbers, Maartje G.
    Vink, Anna-Fleur D.
    Niks, Erik H.
    Westhuis, Ruben H.
    van Zwet, Erik W.
    de Meel, Robert H.
    Rojas-Garcia, Ricardo
    Diaz-Manera, Jordi
    Kuks, Jan B.
    Klooster, Rinse
    Straasheijm, Kirsten
    Evoli, Amelia
    Illa, Isabel
    van der Maarel, Silvere M.
    Verschuuren, Jan J.
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 291 : 82 - 88
  • [15] Treatment of Myasthenia Gravis
    Kumar, Vikas
    Kaminski, Henry J.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) : 89 - 96
  • [16] Complement and myasthenia gravis
    Sanderson, Nicholas S. R.
    MOLECULAR IMMUNOLOGY, 2022, 151 : 11 - 18
  • [17] Myasthenia gravis in childhood
    Anlar, B
    Ozdirim, E
    Renda, Y
    Yalaz, K
    Aysun, S
    Topcu, M
    Topaloglu, H
    ACTA PAEDIATRICA, 1996, 85 (07) : 838 - 842
  • [18] Juvenile myasthenia gravis
    Papazian, Oscar
    Alfonso, Israel
    Araguez, Nayle
    MEDICINA-BUENOS AIRES, 2009, 69 (01) : 71 - 83
  • [19] The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics
    Alahgholi-Hajibehzad, Mahdi
    Kasapoglu, Pinar
    Jafari, Reza
    Rezaei, Nima
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (07) : 859 - 870
  • [20] Myasthenia gravis and thymoma
    De Assis, JL
    Zambon, AA
    Souza, PS
    Marchiori, PE
    ARQUIVOS DE NEURO-PSIQUIATRIA, 1999, 57 (01) : 6 - 13